Experimental anti-blood clotting drug may lower risk of recurrent strokes
New York, Jan 26 (IANS) An experimental drug designed to block blood-clotting proteins may lower the risk of recurrent strokes, according to study.
Stroke is the leading cause of disability worldwide and the second leading cause of death. While one in four people is estimated to have a stroke in their lifetime, many also go on to experience another stroke.
“When patients have transient neurological symptoms due to a minor stroke, we have medications that prevent them from having a further stroke. But despite those medications, a lot of people still go on to have another stroke,” said Richard Bernstein, Professor Department of Neurology’s Division of Stroke and Vascular Neurology at Northwestern University in the US.
Previous research has shown that people with a deficiency of factor XI — a protein known to play a role in blood coagulation, have lower rates of ischemic stroke, the most common type of stroke during which a blood clot blocks the flow of blood and oxygen to the brain.
The new study, published in The Lancet Neurology, aimed to examine the effects of milvexian — a drug designed to inhibit factor XI.
The team randomly assigned more than 2,300 people to receive a regimen of anti-blood clotting medications along with different once- or twice-daily doses of milvexian.
After 90 days, investigators used MRI imaging and found that those participants who received 50-100mg of milvexian twice daily showed a slightly lower risk of recurrent stroke compared to placebo, according to the study.
“It seems like the drug does work to prevent clinical stroke. We don’t know that for sure, but it seems like it, and that has allowed us to pick a dose that hits that sweet spot of lowering the risk of stroke without raising the risk of bleeding too much,” Bernstein said.
“This study also allowed us to observe that counting up strokes on the MRI may not be a good way to tell if these drugs work, and this was the first large study that really tried to use this method, so we’re not going to try that again.”
Moving forward, Bernstein and his collaborators will use the study findings to identify a recommended dose to test in a large clinical trial, he said.